araag2/HINT huggingface dataset:
Clinical trial NCT00409708 (phase 2, status: completed)
Conditions: attention deficit hyperactivity disorder
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: extended release methylphenidate (ritalin la ) plus behavior therapy
SMILES: COC(=O)C(C1CCCCN1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Children of both genders, 6-12 years old

          -  Written informed consent by the parent and the patient (over 7)

          -  Diagnosis of ADHD

          -  Age-appropriate cognitive functioning

          -  All patients who had at least one post-baseline cytogenetic assessment in the core
             study can enter the observation phase.

        Exclusion Criteria:

          -  History of malignant neoplasm

          -  History of seizures (except childhood febrile seizures)

          -  Hyperthyroidism

          -  Concurrent medical condition which may interfere with study

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT01626859 (phase 2/phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: mp-214 low dose, mp-214 middle dose, mp-214 high dose
SMILES: CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1, CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent obtained from the patient before the initiation of any
             study-specific procedures

          -  Patients diagnosed with schizophrenia according to the diagnostic criteria of the
             Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision
             (DSM-IV-TR) criteria for schizophrenia

          -  Patients with normal physical examination, laboratory, vital signs, and/or
             electrocardiogram (ECG)

        Exclusion Criteria:

          -  Patients with a DSM-IV-TR diagnosis of schizoaffective disorder, schizophreniform
             disorder, other psychotic disorders other than schizophrenia, or bipolar I or II
             disorder
Clinical trial NCT01219686 (phase 2/phase 3, status: terminated)
Conditions: unipolar depression
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: escitalopram, pindolol, escitalopram, escitalopram
SMILES: CC(C)NCC(O)COC1=CC=CC2=C1C=CN2, CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Reason stopped: 
    recruitment difficulties
  
Eligibility criteria:

        Inclusion Criteria:

          -  patients aged between 18 and 65 years old

          -  patients suffering from major depression according to DSM-IV with a MADRS score of at
             least 25 and not treated by an antidepressant at the time of inclusion with the
             exception of non-responders to antidepressant for a period of at least 6 weeks or not
             tolerating an ongoing antidepressant necessitating a change of the
             antidepressant(excluding fluoxetine and irreversible MAOI)

          -  informed consent

        Exclusion criteria:

          -  any other Axis I disorder excluding anxiety disorder not dominating the clinical
             picture, nicotine abuse

          -  non-responders to escitalopram in the past

          -  already taking pindolol

          -  pregnancy and breast feeding

          -  contraindication to one of the two treatments (medical conditions, drug treatments)

          -  significant somatic comorbidity interfering with the study procedures

          -  high risk of suicidality

          -  women of childbearing age not having a safe means of contraception
Clinical trial NCT01603069 (phase 2, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: azd3241 300 mg bid, azd3241 600 mg bid, placebo
SMILES: CC(C)OCCN1C2=C(NC=C2)C(=O)NC1=S, CC(C)OCCN1C2=C(NC=C2)C(=O)NC1=S, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Each patient must be able and willing to provide signed and dated informed consent
             prior to the study.

          -  Female and male patients aged 30 to 80 years at the day of enrollment (Visit 1).

          -  Patients must meet the criteria for "Diagnosis of idiopathic Parkinson's disease"
             according to the UKPDS Brain Bank criteria (Hughes et al 1992).

          -  Have a modified Hoehn and Yahr stage 1-2.5.

          -  Having no treatment for Parkinson's disease and have no need to add anti-Parkinson's
             disease treatment during the 14 weeks of study OR are on stable anti-Parkinson's
             disease medication.

        Exclusion Criteria:

          -  Diagnosis is unclear or a suspicion of other Parkinsonian syndromes exists, such as
             secondary Parkinsonism (caused by drugs, toxins, infectious agents, vascular disease,
             trauma, brain neoplasm), Parkinson-plus syndromes or heredodegenerative diseases.

          -  Have undergone surgery for the treatment of Parkinson's disease (eg, pallidotomy, deep
             brain stimulation, fetal tissue transplantation) or have undergone any other brain
             surgery at any time, even for non-Parkinson's disease conditions.

          -  Presence of dyskinesias, motor fluctuations, swallowing difficulties or loss of
             postural reflexes, defined as scoring 2 or more on item 30 of the UPDRS.

          -  Current/history of psychiatric diagnosis of acute psychotic disorder or other primary
             psychiatric diagnoses, i.e. bipolar disorder or MDD, or other psychiatric,
             neurological or behavioral disorders/symptoms that may interfere with conduct of
             study.

          -  Current significant major or unstable respiratory disease, heart disease,
             cerebrovascular disease, hematological disease, hepatic disease, renal disease,
             gastrointestinal (GI) disease, or other major disease as judged by the investigator.
Clinical trial NCT00700570 (phase 2, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: bevacizumab [avastin], capecitabine [xeloda], oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, <=75 years of age;

          -  chemotherapy-naive for stage IV colorectal cancer with unresectable liver metastasis;

          -  >=1 measurable lesion;

          -  ECOG status 0-2.

        Exclusion Criteria:

          -  prior exposure to Avastin;

          -  clinical or radiological evidence of CNS metastases;

          -  uncontrolled hypertension, or clinically significant cardiovascular disease;

          -  ongoing treatment with aspirin (>325mg/day) or other medications known to predispose
             to gastrointestinal ulceration.
Clinical trial NCT01063517 (phase 2, status: active, not recruiting)
Conditions: gastric cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: olaparib, paclitaxel, placebo
SMILES: OC1=NN=C(CC2=CC(C(=O)N3CCN(CC3)C(=O)C3CC3)=C(F)C=C2)C2=CC=CC=C12, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Recurrent or metastatic gastric cancer that has progressed following first
             line-therapy

          -  Confirmed ATM protein status by IHC archival tumour sample

          -  At least one lesion (measurable and/or non-measurable) that can be accurately assessed
             by imaging (CT/MRI) at baseline and follow up visits

        Exclusion Criteria:

          -  More than one prior chemotherapy regimen for the treatment of gastric cancer in the
             metastatic or recurrent setting

          -  Any previous treatment with a PARP inhibitor, including olaparib

          -  Patients with second primary cancer, except; adequately treated non melanoma skin
             cancer, curatively treated in situ cancer of the cervix, or other solid tumours
             curatively treated with no evidence of disease for >5 years
Clinical trial NCT01033487 (phase 2, status: completed)
Conditions: pulmonary disease, chronic obstructive, lung diseases, respiratory tract diseases, chronic obstructive airway disease, copd
ICD codes: J44.9, J44.1, J44.0, J84.115, M05.10, M05.111, M05.112, M05.119, M05.121, M05.122, G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: placebo, active comparator, low dose pf-03635659, mid dose pf-03635659, high dose pf-03635659
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CNC[C@H](O)C1=CC(O)=C(O)C=C1, CC(C)(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=C1)N1CC(C1)OC1=CC=CC(O)=C1, CC(C)(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=C1)N1CC(C1)OC1=CC=CC(O)=C1, CC(C)(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=C1)N1CC(C1)OC1=CC=CC(O)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female (women of non-childbearing potential) subjects between the ages of 40
             and 80 years, inclusive with a diagnosis of moderate COPD (GOLD, 2007 update) and who
             meet the following criteria for GOLD stage II disease

          -  Body Mass Index (BMI) of less than 35.5 kg/m2; and a total body weight >40 kg (88
             lbs).

          -  Current smokers, or ex-smokers who have abstained from smoking for at least 6 months

        Exclusion Criteria:

          -  Subjects having more than 2 exacerbations requiring treatment with oral steroids or
             hospitalization for the treatment of COPD in the previous year.

          -  History of lower respiratory tract infection or significant disease instability during
             the month preceding screening or during the period between screening and
             randomization.
Clinical trial NCT00423150 (phase 2, status: terminated)
Conditions: colorectal neoplasm, head and neck neoplasm, carcinoma, non-small-cell lung, esophageal neoplasm
ICD codes: D02.20, D02.21, D02.22, K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10
Drugs: temozolomide
SMILES: CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participants must be at least 18 years of age.

          -  Participants must have metastatic colorectal cancer (CRC), recurrent or metastatic
             head & neck (H&N) or esophageal cancer, or locally advanced, inoperable, or metastatic
             non-small cell lung cancer (NSCLC).

          -  Participants must have a tumor sample or a blood sample tested positive for the
             presence of the biomarker.

          -  Participants may have up to 3 prior regimens for CRC, up to 3 prior regimens for
             NSCLC, up to 2 prior regimens for H&N and esophageal cancer.

          -  Participants must have at least one measurable lesion.

          -  Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status
             of 0, 1, or 2.

          -  Participants must have adequate hematologic, renal, and liver functions.

          -  Participants must be able to take the study medication capsules orally, or through a
             feeding tube without the capsules being opened.

          -  Participants of childbearing potential must agree to use a medically accepted method
             of contraception.

        Exclusion Criteria:

          -  Participants who have received treatment for a second malignancy within 1 year before
             screening, and are considered to be at risk of relapse within 1 year after screening.

          -  Participants with unstable or progressing central nervous system (CNS) metastasis.
             Participants with known CNS metastasis may be included if a) the subject is
             asymptomatic, b) there is no requirement for steroids or antiseizure medications, or
             the required doses are stable, and c) there is no associated midline shift or (in the
             opinion of the investigator) significant edema.

          -  Participants who received prior temozolomide or dacarbazine treatment
Clinical trial NCT00555581 (phase 2, status: completed)
Conditions: systemic sclerosis
ICD codes: M34.0, M34.89, M34.9, M34.82, M34.83, M34.81, M34.2
Drugs: imatinib mesylate
SMILES: CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1
Eligibility criteria:

        Inclusion Criteria:

          1. Age greater than or equal to eighteen years.

          2. Clinical diagnosis of diffuse systemic sclerosis by ACR criteria, with a stable
             modified Rodnan skin score in the one month preceding introduction of oral Gleevec
             therapy. The modified Rodnan skin score must be greater than or equal to sixteen at
             screening and initiation of therapy.

          3. Disease duration of less than or equal to 10 years.

          4. Estimated ejection fraction of greater than 50% by echocardiography

        Exclusion Criteria:

          1. Inability to render informed consent in accordance with institutional guidelines.

          2. Disease duration of greater than 10 years.

          3. Patients with mixed connective tissue disease or "overlap" (i.e. those who satisfy
             more than one set of ACR criteria for a rheumatic disease.)

          4. Ongoing treatment with other immunosuppressive therapies including cyclophosphamide,
             azathioprine, mycophenolic acid, methotrexate, or cyclosporine, or use of those
             medications within 3 months of trial entry.

          5. Concurrent serious medical condition which in the opinion of the investigator makes
             the patient inappropriate for this study such as uncontrollable CHF, arrhythmia,
             severe pulmonary or systemic hypertension, severe GI involvement, serum creatinine of
             greater than 2.0, active infection, severe diabetes, unstable atherosclerotic
             cardiovascular disease, malignancy, HIV, or severe peripheral vascular disease.

          6. The use of other anti-fibrotic agents including colchicine, D-penicillamine,
             minocycline, or Type 1 oral Collagen in the three months prior to enrollment.

          7. Limited scleroderma.

          8. Systemic sclerosis-like illness associated with environmental or ingested agents such
             as toxic rapeseed oil, vinyl chloride, or bleomycin.

          9. A positive pregnancy at entry into this study. Men and women with reproductive
             potential will be required to use effective means of contraception through the course
             of the study.

         10. Use in the prior month of corticosteroids at doses exceeding the equivalent of
             prednisone 10 mg daily. Use of corticosteroid at < 10 mg of prednisone can continue
             but not be increased during the course of the study.

         11. Participation in another clinical research study involving the evaluation of another
             investigational drug within ninety days of entry into this study.

         12. The presence of severe lung disease as defined by a diffusion capacity of less than
             30% of predicted.
Clinical trial NCT01258907 (phase 2, status: completed)
Conditions: atherosclerosis
ICD codes: I67.2, I70.90, I70.91, I70.0, I70.1, I70.8, I25.83
Drugs: mldl1278a, mldl1278a, placebo, statin, stable dose
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Evidence of qualifying vessel (carotid or aortic) plaque inflammation

          -  Documented atherosclerotic vascular disease clinically stable for at least 3 months
             prior to screening or type 2 diabetes mellitus with elevated cardiovascular risk

          -  Use of a stable dose of statin therapy for at least 6 weeks prior to screening.
             Patients must be capable of maintaining statin therapy at a current dose level from
             screening until the last follow-up visit.

          -  For patients taking angiotensin-converting enzyme (ACE) inhibitors (ACE-I) or
             angiotensin-receptor blockers (ARBs), non-statin lipid-modifying therapy,
             thiazolidinediones, inhaled steroids, or leukotriene modifying agents, use of a stable
             dose for at least 6 weeks prior to screening and capable of continuing with that dose
             for the duration of the study

        Exclusion Criteria:

          -  Occurrence of a cardiovascular event < 6 months prior to screening

          -  Pregnant, planning to become pregnant during the study, or breastfeeding

          -  Clinically significant abnormal laboratory values or abnormal ECG or vital signs

          -  History of anaphylactic reactions

          -  Newly discovered Type 2 diabetes mellitus (T2DM) (prior to study entry) or medical
             treatment for T2DM started < 3 months prior to study entry

          -  Use of insulin, corticosteroids (oral, rectal, or injectable), or other
             immunosuppressive medications

          -  Current or recent (within 4 weeks prior to screening) infection, including signs,
             symptoms or serology of any infection, including HIV, hepatitis B or C

          -  Impaired renal function

          -  History of malignancy within 2 years prior to screening

          -  Current life-threatening condition other than vascular disease that may prevent a
             patient from completing the study

          -  Use of an investigational drug or biologic within 30 days or 5 half-lives (whichever
             is longer) prior to the first dose of study medication

          -  Exposure to substantial radiation within 12 months prior to screening
Clinical trial NCT01487096 (phase 2, status: completed)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: teriflunomide, placebo (placebo for teriflunomide)
SMILES: C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Clinically confirmed multiple sclerosis [MS];

          -  Expanded Disability Status Scale [EDSS] score less or equal to 6;

          -  Two documented relapses in the previous 3 years, and one clinical relapse during the
             preceding year;

          -  Screening magnetic resonance imaging [MRI] scan fulfilling the criteria for a
             diagnosis of MS.

        Exclusion Criteria:

          -  Clinically relevant cardiovascular, hepatic, hematologic, neurological, endocrine or
             other major systemic disease;

          -  Pregnant or nursing woman;

          -  Wish to parent children during the trial or following the trial (men and women were
             required to practice effective contraception during the trial and for 24 months after
             drug discontinuation);

          -  Prior treatment with interferon [IFN], gamma-globulin, glatiramer acetate, or other
             noncorticosteroid immunomodulatory therapies in the 4 months prior to the trial;

          -  Use of cladribine, mitoxantrone, or other immunosuppressant agents such as
             azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate before
             enrollment;

          -  Any known condition or circumstance that would prevent in the investigator's opinion
             compliance or completion of the study.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00543413 (phase 2, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: mk8141, comparator: placebo (unspecified), enalapril
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  You are 35 to 65 years of age

          -  In the past 14 days you have not been treated for hypertension

          -  In the past 14 days you have not taken more than 2 medications to treat high blood
             pressure

          -  You are a woman who is not able to have children or do not use birth control

        Exclusion Criteria:

          -  You are taking more than 2 medications to treat high blood pressure

          -  You have a history of a stroke, transient ischemic attack (TIA), heart attack,
             congestive heart failure, coronary artery bypass surgery

          -  You have Type 1 or 2 diabetes mellitus

          -  You have an active liver disease, gallbladder disease, or bowel disease

          -  You are HIV positive

          -  You have certain types of cancer

          -  You abuse drug or alcohol

          -  You have participated in another clinical study in last 4 weeks
Clinical trial NCT01644617 (phase 2, status: completed)
Conditions: rhinitis, allergic, perennial, rhinitis, allergic, nonseasonal
ICD codes: J30.0, J31.0, J30.89, J30.9, A50.05, J30.2, J30.1, J30.0, J31.0, J30.89, J30.9, A50.05, J30.2, J30.1
Drugs: placebo, mk-8237 6 du, mk-8237 12 du
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  History of allergic rhinitis/rhinoconjunctivitis to house dust of 1 year duration or
             more (with or without asthma)

          -  If female of childbearing potential, has a negative urine pregnancy test at screening
             and agrees to remain abstinent or use (or have their partner use) 2 acceptable methods
             of birth control within the projected duration of the study.

        Exclusion Criteria:

          -  Sensitized and regularly exposed to animal dander and molds, (e.g. present in the
             home, job, etc.)

          -  Sensitized and regularly exposed to seasonal allergens (i.e., birch or grass pollen)

          -  Immunosuppressive treatment within 3 months prior to screening (except steroids for
             allergic and asthma symptoms)

          -  History of chronic urticaria and/or angioedema within 2 years prior to screening

          -  Previous immunotherapy treatment with any HDM allergen for more than 1 month within 3
             years prior to screening

          -  Ongoing treatment with any specific immunotherapy

          -  History of anaphylaxis with cardiorespiratory symptoms with prior immunotherapy, due
             to an unknown cause or to an inhalant allergen

          -  Unstable uncontrolled/partially controlled or severe asthma, or life-threatening
             asthma attack or an occurrence of any clinical deterioration of asthma that resulted
             in emergency treatment, hospitalization due to asthma, or treatment with systemic
             corticosteroids (but allowing short-acting beta agonists [SABA]) within 3 months prior
             to screening

          -  Asthma requiring medium- or high-dose inhaled corticosteroid (ICS) within 12 months
             prior to screening

          -  Chronic sinusitis within 2 years prior to screening

          -  Nasal condition that could confound the efficacy or safety assessments (e.g., nasal
             polyps)

          -  Pregnant, breastfeeding or planning to become pregnant during the study

          -  Participation in a different investigational study at any site during the same time
             frame of this study

          -  Direct association with the administration of the study or a family member of the
             study staff